Ludovic Barault
YOU?
Author Swipe
View article: A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection Open
Background: O-6-methylguanine-DNA methyltransferase is responsible for the direct repair of O6-methylguanine lesions induced by alkylating agents, including temozolomide. O-6-methylguanine-DNA methyltransferase promoter hypermethylation is…
View article: DNA demethylation triggers cell free DNA release in colorectal cancer cells
DNA demethylation triggers cell free DNA release in colorectal cancer cells Open
Background Liquid biopsy based on cell-free DNA (cfDNA) analysis holds significant promise as a minimally invasive approach for the diagnosis, genotyping, and monitoring of solid malignancies. Human tumors release cfDNA in the bloodstream …
View article: Transcriptome‐wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer
Transcriptome‐wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer Open
Multiple strategies are continuously being explored to expand the drug target repertoire in solid tumors. We devised a novel computational workflow for transcriptome‐wide gene expression outlier analysis that allows the systematic identifi…
View article: Preclinical efficacy of carfilzomib in <i>BRAF</i> ‐mutant colorectal cancer models
Preclinical efficacy of carfilzomib in <i>BRAF</i> ‐mutant colorectal cancer models Open
Serine/threonine‐protein kinase B‐raf ( BRAF ) mutations are found in 8–15% of colorectal cancer patients and identify a subset of tumors with poor outcome in the metastatic setting. We have previously reported that BRAF‐ mutant human cell…
View article: Data from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
Data from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients Open
The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond to immune-checkpoint blockade. We previously reported that the t…
View article: Supplementary Figure from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
Supplementary Figure from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients Open
Supplementary Figure from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
View article: Supplementary Figure from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
Supplementary Figure from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients Open
Supplementary Figure from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
View article: Data from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
Data from Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients Open
The majority of metastatic colorectal cancers (mCRC) are mismatch repair (MMR) proficient and unresponsive to immunotherapy, whereas MMR-deficient (MMRd) tumors often respond to immune-checkpoint blockade. We previously reported that the t…
View article: Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation Open
SNP ID.
View article: Data from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Data from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation Open
Purpose:Current glioma diagnostic guidelines call for molecular profiling to stratify patients into prognostic and treatment subgroups. In case the tumor tissue is inaccessible, cerebrospinal fluid (CSF) has been proposed as a reliable tum…
View article: Supplementary Figures S1 - S3 from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer
Supplementary Figures S1 - S3 from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer Open
Supplementary Figure S1. Copy number increase of MDM2 gene at progression after vemurafenib+panitumumab. Supplementary Figure S2. Representative examples of colorectal carcinomas bearing BRAF mutations and MET gene copy number gain. Supple…
View article: Supplementary Figure Legends from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer
Supplementary Figure Legends from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer Open
Supplementary Figure Legends
View article: Data from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer
Data from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer Open
A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR and BRAF inhibition with panitumumab plus vemurafenib. Pre-existing cells with increased MET gene copy number in the archival tumor tissue…
View article: Supplementary Tables 1 - 3 from <i>BRAF</i> V600E Is a Determinant of Sensitivity to Proteasome Inhibitors
Supplementary Tables 1 - 3 from <i>BRAF</i> V600E Is a Determinant of Sensitivity to Proteasome Inhibitors Open
XLSX file - 144K, Supplementary table S1. List of compounds employed in the present work. Supplementary Table S2. List of t-tests p values comparing the responses of the different mutant cell lines to a given drug concentration with the re…
View article: Data from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer
Data from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer Open
A patient with metastatic BRAF-mutated colorectal cancer initially responded to combined EGFR and BRAF inhibition with panitumumab plus vemurafenib. Pre-existing cells with increased MET gene copy number in the archival tumor tissue…
View article: Supplementary Information 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Supplementary Information 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation Open
Supplementary Figures 1-4, Supplementary Tables S1-S13, Description of Supplementary Data 1-3, Supplementary Materials and Methods, Supplementary References.
View article: Supplementary Tables 1 - 3 from <i>BRAF</i> V600E Is a Determinant of Sensitivity to Proteasome Inhibitors
Supplementary Tables 1 - 3 from <i>BRAF</i> V600E Is a Determinant of Sensitivity to Proteasome Inhibitors Open
XLSX file - 144K, Supplementary table S1. List of compounds employed in the present work. Supplementary Table S2. List of t-tests p values comparing the responses of the different mutant cell lines to a given drug concentration with the re…
View article: Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation Open
NGS analysis - Complete dataset.
View article: Supplementary Figures 1 - 4 from <i>BRAF</i> V600E Is a Determinant of Sensitivity to Proteasome Inhibitors
Supplementary Figures 1 - 4 from <i>BRAF</i> V600E Is a Determinant of Sensitivity to Proteasome Inhibitors Open
PDF file - 635K, Supplementary Figure S1. Genotypes included in the combinatorial genetic matrix. PTEN or RB1 were silenced by shRNA in isogenic KI cells.
View article: Data from <i>BRAF</i> V600E Is a Determinant of Sensitivity to Proteasome Inhibitors
Data from <i>BRAF</i> V600E Is a Determinant of Sensitivity to Proteasome Inhibitors Open
A critical step toward defining tailored therapy in patients with cancer is the identification of genetic interactions that may impair—or boost—the efficacy of selected therapeutic approaches. Cell models able to recapitulate combinations …
View article: Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation Open
Primers and probes.
View article: Supplementary Information 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Supplementary Information 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation Open
Supplementary Figures 1-4, Supplementary Tables S1-S13, Description of Supplementary Data 1-3, Supplementary Materials and Methods, Supplementary References.
View article: Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation Open
NGS analysis - Complete dataset.
View article: Supplementary Figures S1 - S3 from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer
Supplementary Figures S1 - S3 from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer Open
Supplementary Figure S1. Copy number increase of MDM2 gene at progression after vemurafenib+panitumumab. Supplementary Figure S2. Representative examples of colorectal carcinomas bearing BRAF mutations and MET gene copy number gain. Supple…
View article: Supplementary Methods, Tables S1 - S2 from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer
Supplementary Methods, Tables S1 - S2 from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer Open
Supplementary Table S1. List of genes and exons analyzed by targeted next-generation sequencing. Supplementary Table S2. Summary of molecular data from the ISH and sequencing analyses conducted on both the pre-treatment primary tumor and t…
View article: Supplementary Methods, Tables S1 - S2 from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer
Supplementary Methods, Tables S1 - S2 from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer Open
Supplementary Table S1. List of genes and exons analyzed by targeted next-generation sequencing. Supplementary Table S2. Summary of molecular data from the ISH and sequencing analyses conducted on both the pre-treatment primary tumor and t…
View article: Supplementary Figure Legends from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer
Supplementary Figure Legends from MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in <i>BRAF</i>-Mutated Colorectal Cancer Open
Supplementary Figure Legends
View article: Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation Open
SNP ID.
View article: Supplementary Figures 1 - 4 from <i>BRAF</i> V600E Is a Determinant of Sensitivity to Proteasome Inhibitors
Supplementary Figures 1 - 4 from <i>BRAF</i> V600E Is a Determinant of Sensitivity to Proteasome Inhibitors Open
PDF file - 635K, Supplementary Figure S1. Genotypes included in the combinatorial genetic matrix. PTEN or RB1 were silenced by shRNA in isogenic KI cells.
View article: Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation Open
Primers and probes.